• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The relationship between diuretics and serum cholesterol in Hypertension Detection and Follow-up Program participants.

作者信息

Williams W R, Schneider K A, Borhani N O, Schnaper H W, Slotkoff L M, Ellefson R D

机构信息

Hypertension Detection and Follow-up Program, National Heart, Lung, and Blood Institute, Bethesda, MD 20205.

出版信息

Am J Prev Med. 1986 Sep-Oct;2(5):248-55.

PMID:3453187
Abstract

The effect of diuretics, mainly chlorthalidone, on serum cholesterol was studied in 7,006 of the Hypertension Detection and Follow-up Program (HDFP) hypertensive patients not on antihypertensive medication at baseline. Several investigators have reported that diuretic therapy increases serum cholesterol in treated subjects. However, data from two long-term studies indicated that no increase in cholesterol occurred after two years of diuretic treatment. In the present study, yearly changes in serum cholesterol in hypertensives treated with diuretics were observed. The results were in agreement with those reported from both short-term and long-term studies, in that a significant increase in cholesterol was observed in six months to one year into the study but not from the second to the fifth year of therapy. In fact, the serum cholesterol levels were the same as baseline values after two years of drug treatment and decreased slightly thereafter. In the untreated group, no change or a decrease in serum cholesterol was observed during the course of the study. The possible causes for changes in serum cholesterol concentration such as regression to the mean, change in body weight, baseline cholesterol concentration, and the action mechanism of diuretic drugs are discussed.

摘要

相似文献

1
The relationship between diuretics and serum cholesterol in Hypertension Detection and Follow-up Program participants.
Am J Prev Med. 1986 Sep-Oct;2(5):248-55.
2
Serum cholesterol during treatment of hypertension with diuretic drugs.使用利尿药物治疗高血压期间的血清胆固醇
Arch Intern Med. 1984 Apr;144(4):710-4.
3
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes.基于利尿剂的治疗对伴有或不伴有糖尿病的单纯收缩期高血压患者致命结局的长期影响。
Am J Cardiol. 2005 Jan 1;95(1):29-35. doi: 10.1016/j.amjcard.2004.08.059.
4
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).血管紧张素转换酶抑制剂或钙通道阻滞剂与利尿剂治疗高危高血压患者的肾脏转归:抗高血压和降脂治疗预防心脏病发作试验(ALLHAT)报告
Arch Intern Med. 2005 Apr 25;165(8):936-46. doi: 10.1001/archinte.165.8.936.
5
Blood pressure and serum potassium levels in hypertensive patients receiving or not receiving antihypertensive treatment.接受或未接受抗高血压治疗的高血压患者的血压和血清钾水平。
Clin Exp Hypertens. 2007 Nov;29(8):563-73. doi: 10.1080/10641960701744103.
6
Effect of thiazide-based therapy on serum alkaline phosphatase. Hypertension Detection and Follow-up Group.噻嗪类药物治疗对血清碱性磷酸酶的影响。高血压检测与随访组。
J Hum Hypertens. 1991 Aug;5(4):333-8.
7
NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).4,4'-硫代双(6-叔丁基间甲酚)(CAS编号:96-69-5)在F344/N大鼠和B6C3F1小鼠中的NTP毒理学和致癌性研究(饲料研究)
Natl Toxicol Program Tech Rep Ser. 1994 Dec;435:1-288.
8
Different effects of metoprolol and chlorthalidone on serum lipoprotein levels in mild hypertension. Possible implications for coronary heart disease risk status.美托洛尔和氯噻酮对轻度高血压患者血清脂蛋白水平的不同影响。对冠心病风险状况的潜在影响。
Isr J Med Sci. 1984 Dec;20(12):1169-76.
9
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.利尿剂在预防心力衰竭中的作用:预防心脏病发作的抗高血压和降脂治疗试验
Circulation. 2006 May 9;113(18):2201-10. doi: 10.1161/CIRCULATIONAHA.105.544031. Epub 2006 May 1.
10
Comparison of chlorthalidone, propranolol and bopindolol in six-month treatment of arterial hypertension.氯噻酮、普萘洛尔和波吲洛尔治疗动脉高血压六个月的比较。
Int J Clin Pharmacol Res. 1998;18(2):73-8.

引用本文的文献

1
Antihypertensive drug class and impaired fasting glucose: a risk association study among Chinese patients with uncomplicated hypertension.抗高血压药物类别与空腹血糖受损:一项针对中国单纯性高血压患者的风险关联研究。
BMC Clin Pharmacol. 2008 Sep 10;8:6. doi: 10.1186/1472-6904-8-6.
2
Diuretics should continue to be one of the preferred initial therapies in the management of hypertension: the argument for.利尿剂应继续作为高血压管理中首选的初始治疗方法之一:支持该观点的理由。
J Clin Hypertens (Greenwich). 2005 Feb;7(2):111-6; quiz 121-2. doi: 10.1111/j.1524-6175.2005.03943.x.
3
Periodic health examination, 1993 update: 2. Lowering the blood total cholesterol level to prevent coronary heart disease. Canadian Task Force on the Periodic Health Examination.
定期健康检查,1993年更新版:2. 降低血液总胆固醇水平以预防冠心病。加拿大定期健康检查特别工作组。
CMAJ. 1993 Feb 15;148(4):521-38.
4
Influence of dietary sodium restriction on lipid metabolism.饮食钠限制对脂质代谢的影响。
Clin Investig. 1993 Dec;71(12):990-2. doi: 10.1007/BF00180029.
5
Lipid profile during antihypertensive treatment. The SLIP Study Group. Study on Lipids with Isoptin Press.抗高血压治疗期间的血脂情况。SLIP研究小组。异搏定降压血脂研究。
Drugs. 1993;46 Suppl 2:16-23. doi: 10.2165/00003495-199300462-00005.
6
Effects of diuretic drugs on the lipid profile.利尿药对血脂谱的影响。
Drugs. 1988;36 Suppl 2:33-40. doi: 10.2165/00003495-198800362-00007.
7
Do different hemodynamic effects of antihypertensive drugs translate into different safety profiles?
Eur J Clin Pharmacol. 1990;38 Suppl 2:S134-8. doi: 10.1007/BF01409483.
8
Management of mild hypertension. Selecting an antihypertensive regimen.轻度高血压的管理。选择抗高血压治疗方案。
West J Med. 1991 Jan;154(1):78-87.
9
Adverse effects of diuretics.利尿剂的不良反应。
Drug Saf. 1992 Sep-Oct;7(5):364-73. doi: 10.2165/00002018-199207050-00004.